Will These Stocks Decline? United Therapeutics Corporation (UTHR), Ionis Pharmaceuticals Inc (IONS)


United Therapeutics Corporation (NASDAQ:UTHR):

Stock’s Trading Stats:

United Therapeutics Corporation (NASDAQ:UTHR) surged 1.35% Friday and closed at $112.93. The company’s market capitalization is at $5.19Billion with an average trading volume of 822,735.00. The total number of Outstanding Shares Held by the company are 45.35 Million.

Recent Press Release:

United Therapeutics Corporation (UTHR) on March 8, 2016 declared that Roger Jeffs, Ph.D., President and Co-Chief Executive Officer of United Therapeutics, will provide an overview and update on the company’s business at the Barclays Global Healthcare Conference in Miami Beach, Florida.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening diseases.

Ionis Pharmaceuticals Inc (NASDAQ:IONS):

Stock’s Trading Stats:

Ionis Pharmaceuticals Inc (NASDAQ:IONS) closed at $41.02 Friday by showing an increase of 1.28%. The total number of outstanding shares held by the company are 120.66 Million with the total market capitalization of $5.01 billion. The number of shares traded on the last trading session are 120.66 Million.

Recent Press Release:

Ionis Pharmaceuticals Inc (IONS) on April 1, 2016 declared that administration will present a company overview at the following shareholder conferences:

  • 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 in New York, NY;
  • 41st Annual Deutsche Bank Health Care Conference on Thursday, May 5, 2016 in Boston, MA; and
  • Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 in Rancho Palos Verdes, CA.

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases.  Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development.  Drugs presently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned partner, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy.